| Identification | Back Directory | [Name]
Dynorphin A (1-13) | [CAS]
72957-38-1 | [Synonyms]
Dyn(1-13)
YGGFLRRIRPKLK
DYNORPHIN 1-13
DYNORPHIN A (1-13)
Dynorphin A1-13【pig】
Dynorphin A(1-13)【pig】
Dynorphin A(1-13)【rat】
Dynphin A (1-13) Acetate
1-13-Dynorphin A (swine)
DYNORPHIN A(HUMAN, 1-13)
Porcine dynorphin A(1-13)
DYNORPHIN A (1-13), PORCINE
Dynorphin A (1-13) USP/EP/BP
DYNORPHIN A PORCINE FRAGMENT 1-13
Dynorphin (1-17), Dynorphin (1-14)
Dynorphin A (1-13) (human, porcine)
dynorphin A, porcine, fragment 1-13 acetate
DYNORPHIN A (HUMAN, 1-13) (PORCINE, RAT, BOVINE)
DYNORPHIN A (2-13) SYNTHETIC >97% OPIOID AGONIST
DYNORPHIN A (1-13) SYNTHETIC >97% OPIOID AGONIST
TYR-GLY-GLY-PHE-LEU-ARG-ARG-ILE-ARG-PRO-LYS-LEU-LYS
L-TYR-GLY-GLY-PHE-LEU-ARG-ARG-ILE-ARG-PRO-LYS-LEU-LYS
H-TYR-GLY-GLY-PHE-LEU-ARG-ARG-ILE-ARG-PRO-LYS-LEU-LYS-OH
DYNORPHIN A (HUMAN, 1-13) (PORCINE, RAT, BOVINE) 5ACOH 6H2O
TYR-GLY-GLY-PHE-LEU-ARG-ARG-ILE-ARG-PRO-LYS-LEU-LYS PORCINE
TYR-GLY-GLY-PHE-LEU-ARG-ARG-ILE-ARG-PRO-LYS-LEU-LYS 5ACOH 6H2O
Porcine dynorphin A(1-13),Dynorphin A Porcine Fragment 1-13, BR
H-Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys-OH acetate salt | [EINECS(EC#)]
635-974-1 | [Molecular Formula]
C75H126N24O15 | [MDL Number]
MFCD00076366 | [MOL File]
72957-38-1.mol | [Molecular Weight]
1603.95 |
| Chemical Properties | Back Directory | [density ]
1.39±0.1 g/cm3(Predicted) | [RTECS ]
JV7436666 | [storage temp. ]
Inert atmosphere,Store in freezer, under -20°C | [form ]
Solid | [pka]
3.31±0.10(Predicted) | [color ]
White to off-white | [Water Solubility ]
Water: ≥ 60 mg/mL (37.41 mM) | [Sequence]
H-Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-Pro-Lys-Leu-Lys-OH | [Cosmetics Ingredients Functions]
ANTI-SEBUM
SKIN PROTECTING | [InChIKey]
OVVIBUHLQIYUEU-JASZZEBFNA-N |
| Hazard Information | Back Directory | [Description]
Dynorphin A(1-13), a tridecapeptide of the endogenous opioid peptides, has modest effects in reducing mild opiate withdrawal in humans. Previous studies revealed that dynorphin also potentiates the analgesic effect of morphine in morphine-tolerant rats and mice. The therapeutic potential of dynorphin A(1-13) is limited due to extensive metabolism by human metabolic enzymes resulting in an in vivo half-life of less than one minute. Chemical modifications of dynorphin A(1-13), such as N-methylation of Tyr1 and amidation of the C-terminus have been shown to be effective in protecting against the proteolytic enzymes in human plasma[1]. | [Uses]
Porcine dynorphin A (1-13) is a potent, endogenous κ opioid receptor agonist and is antinociceptive at physiological concentrations. | [Application]
Dynorphin A (1-13) has been used as a test compound in the field asymmetric waveform ion mobility spectrometry coupled to mass spectrometry (FAIMS/IMS/MS). | [Biochem/physiol Actions]
Dynorphin A (1-13), a bioactive product of dynorphin A displays interaction with N-methyl- D-aspartate (NMDA) as well as with opioid receptors. It elevates intracellular calcium [Ca2+]i level and contributes to the loss of neurons affecting neuronal viability. | [in vivo]
Dynorphin A (1-13) exposure (33 μM) causes a significant loss in neuronal viability at 4 h with a visible destruction in neuronal morphology seen at 16 h. Exposure to dynorphin A (1-13) causes acute increases in [Ca2+]i in individual neurons similar to increases seen with acute NMDA treatment. Continuous exposure to dynorphin A (1-13) (100 μM) causes a significant loss of neurons over time[1]. | [IC 50]
κ Opioid Receptor/KOR | [References]
[1] B BRUGOS; G H. Metabolism of dynorphin A(1-13).[J]. Pharmazie, 2004. |
|
|